Rosuvastatin
24 interactions 2 explained in plain EnglishRosuvastatin is a statin used to lower cholesterol and reduce the risk of heart attack and stroke. Read the full Rosuvastatin drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Rosuvastatin Colchicine Colcrys Explained An increased risk of myopathy or rhabdomyolysis Details Rosuvastatin Asciminib Scemblix Increased rosuvastatin exposure and an increased risk of rosuvastatin-related adverse effects Details Rosuvastatin Belumosudil Rezurock Explained Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Abiraterone Abirtega Increased rosuvastatin exposure and increased risk of myopathy Details Rosuvastatin Capmatinib Tabrecta Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Cyclosporine Injection Atopica Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Cyclosporine Ophthalmic Cequa Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Daptomycin Cubicin Increased risk of myopathy or rhabdomyolysis Details Rosuvastatin Daptomycin Injection Cubicin Increased risk of myopathy or rhabdomyolysis Details Rosuvastatin Darolutamide Nubeqa Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Elacestrant Orserdu Increased rosuvastatin exposure and an increased risk of rosuvastatin-related adverse effects Details Rosuvastatin Eluxadoline Viberzi Increased rosuvastatin exposure Details Rosuvastatin Enasidenib Idhifa Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Febuxostat Uloric Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Fostamatinib Tavalisse Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Gemfibrozil Lopid Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Leflunomide Arava Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Rosuvastatin Leniolisib Joenja Increased BCRP/OATP1B1/OATP1B3 substrate exposure Details Rosuvastatin Letermovir Injection Prevymis Increased statins exposure and an increased risk for myopathy and rhabdomyolysis Details Rosuvastatin Midostaurin Rydapt Increased BCRP and OATP1B1 substrate exposure Details Rosuvastatin Niacin Endur-Acin An increased risk of myopathy or rhabdomyolysis DetailsModerate
Rosuvastatin Encorafenib Braftovi Increased rosuvastatin exposure and an increased risk of rosuvastatin-related toxicities Details Rosuvastatin Fostemsavir Rukobia Increased exposure of the HMG-CoA reductase inhibitor Details Rosuvastatin Lanthanum Fosrenol® Reduced statin bioavailability DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist